TL;DR
The most-studied repair peptide that almost nobody has real human data on.
What is it? A 15-amino-acid fragment originally isolated from stomach juice. Weirdly stable — survives stomach acid, which most peptides don't.
What does it do? In animal studies it dramatically speeds tendon, gut, nerve, and skin healing by ramping up new blood vessel growth and pulling repair cells straight to the injury site.
Does the evidence hold up? 544 papers. Almost all rats. Three tiny human pilots. One Phase II trial finally registered. The gap between "lab magic" and "proven in people" is still huge.
Who uses it? Guys with stubborn tendon issues, post-surgery recovery, and functional-medicine clinics chasing faster healing.
Bottom line? Best animal repair data in the peptide category. Human proof is overdue — and criminally late.
What It Is
BPC-157 is a synthetic pentadecapeptide — a chain of 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) — derived from a naturally occurring protein found in human gastric juice. The "BPC" stands for Body Protection Compound. It was first isolated and characterized by researchers at the University of Zagreb in the early 1990s under the direction of Predrag Sikiric, who has led BPC-157 research for over three decades.
Unlike most peptides in the optimization space, BPC-157 is remarkably stable in human gastric juice. This means it can be administered orally and still retain biological activity — an unusual property for a peptide that is typically destroyed by digestive enzymes. This gastric stability is one reason it has generated significant research interest, particularly for gastrointestinal applications, and it is the single structural feature that separates BPC-157 from essentially every other injection-only tissue-repair peptide.
A 2025 systematic review by Vasireddi et al. in the HSS Journal identified 544 published articles on BPC-157 from 1993 to 2024, making it one of the most extensively studied research peptides. PubMed now indexes over 190 BPC-157 results, with research output roughly quadrupling since 2020. Despite that volume, only three published human pilot studies exist. The gap between preclinical enthusiasm and clinical evidence is the defining feature of BPC-157's present evidence profile, and understanding that gap is the most important context for anyone considering its use.
BPC-157 also sits at the center of the most important peptide-regulatory story of 2026: HHS Secretary Robert F. Kennedy Jr.'s February 27, 2026 announcement that approximately 14 of the 19 FDA Category 2 peptides — BPC-157 among them — will be reclassified back to Category 1 and again made available through licensed compounding pharmacies. As of April 2026, the formal PCAC review and FDA implementation are still pending; BPC-157 cannot yet be legally compounded in the US.
Mechanism of Action
BPC-157 is a pleiotropic peptide — it exerts effects through multiple interconnected molecular pathways rather than a single receptor target. This multi-pathway activity is why it appears across such diverse tissue repair contexts (tendon, gut, nerve, bone, muscle, endothelium) rather than being limited to one tissue type.
- VEGFR2-Akt-eNOS pathway (angiogenesis) — BPC-157 upregulates vascular endothelial growth factor receptor-2 (VEGFR2) expression and activation, enhancing the angiogenic response to existing VEGF concentrations. Downstream, this activates the PI3K-Akt-eNOS cascade, promoting nitric oxide production, vasodilation, and new blood vessel formation at injury sites. Critically, BPC-157 does not increase VEGF-A levels — it sensitizes cells to existing VEGF by increasing receptor density (Hsieh et al., 2017; PMID 27847966).
- Src-Caveolin-1-eNOS pathway (independent NO production) — Research from Chang Gung University in Taiwan, independent of the Zagreb group, demonstrated that BPC-157 promotes phosphorylation of Src kinase and Caveolin-1, disrupting the inhibitory Cav-1–eNOS complex and directly promoting endothelium-dependent vasodilation and nitric oxide production in a dose-dependent manner. This provides a VEGF-independent parallel pathway for NO-mediated vascular repair (Hsieh et al., 2020; PMID 33051481).
- FAK-paxillin pathway (cell migration) — BPC-157 phosphorylates focal adhesion kinase (FAK) at Tyr397, accelerating fibroblast migration velocity. This cytoskeletal reorganization pathway governs cell migration, adhesion, and wound closure at the cellular level and is central to how fibroblasts reach and repopulate injured tissue.
- Growth hormone receptor upregulation — Animal models show BPC-157 increases growth hormone receptor expression in tendon fibroblasts at both mRNA and protein levels, amplifying local IGF-1 sensitivity without altering systemic hormone levels. This enhances collagen synthesis and tissue repair capacity specifically at injury sites rather than through systemic hormone elevation (Chang et al., 2014; PMID 25415472).
- Nitric oxide system modulation (bidirectional) — BPC-157 does not simply increase or decrease NO. It modulates the system bidirectionally: upregulating protective eNOS (Nos3) while downregulating pathological inducible NOS (iNOS/Nos2) during inflammation. This dual modulation reduces nitrosative stress while preserving NO's essential vascular and healing functions.
- ERK1/2 signaling — Activation of the extracellular signal-regulated kinase pathway facilitates endothelial proliferation, smooth muscle tone regulation, and myofibroblast organization during repair.
- Dopamine and serotonin system interaction — Rodent studies show BPC-157 influences the dopaminergic and serotonergic systems, counteracting dopamine-related lesions and modulating neurotransmitter balance. It restores glutamatergic signaling after NMDA receptor overactivation and modulates adrenergic balance, providing the mechanistic basis for its reported CNS effects (Vukojevic et al., 2022).
- GI cytoprotection — As a gastric peptide, BPC-157 shows strong cytoprotective effects on gastric and intestinal mucosa, including protection against NSAID-induced damage, ethanol damage, and various inflammatory lesions. Gastric mucosal blood flow restoration reaches approximately 90% of baseline within 24 hours in NSAID-induced ulcer models (Sikiric et al., 2011).
- Vascular occlusion counteraction — Recent Zagreb studies demonstrate BPC-157 can rapidly activate collateral blood vessel pathways, effectively bypassing occluded or damaged vessels in superior mesenteric artery and vein occlusion models — a mechanism now framed by Sikiric's group as the "cytoprotection / organoprotection" hypothesis.
What the Research Shows
BPC-157 has been studied across a wide range of injury and disease states in animal models. The 2025 Vasireddi systematic review screened 544 articles and included 36 meeting full criteria — 35 preclinical and 1 clinical. The preclinical evidence is large and consistent, but almost entirely from rodent models.
- Tendon and ligament repair — Multiple rat studies show accelerated healing of Achilles tendon transections, MCL injuries, and muscle crush injuries. Tendon-to-bone healing was improved in rotator cuff and Achilles detachment models, and BPC-157 opposed the healing-aggravation caused by concurrent corticosteroids (Staresinic et al., 2003; Krivic et al., 2008). In vitro, BPC-157 improved tendon fibroblast survival under stress, increased cell migration indices, cell proliferation, and growth hormone receptor expression.
- Gut healing — The most robust area of BPC-157 research. Demonstrated protection against inflammatory bowel disease models, NSAID-induced GI lesions, gastric ulcers, esophageal reflux damage, intestinal anastomosis healing, and fistula closure in rats. Stabilizes the gut microbiome and regulates the brain-gut axis (Sikiric et al., 2011; 2016).
- Wound healing — Accelerated closure of incisional and excisional wounds in rat models, including diabetic wound healing where healing is typically impaired. Higher numbers of collagen, reticulin, and blood vessel development compared to control groups.
- Neuroprotection — Protection against peripheral nerve damage, dopaminergic neurotoxicity, cuprizone-induced demyelination, and traumatic brain injury in rodent models. BPC-157 also counteracts NMDA receptor overactivation and restores glutamatergic signaling (Vukojevic et al., 2022).
- Bone healing — Improved osteogenic activity and fracture healing in rabbit segmental bone defect models and tendon-to-bone healing in rats.
- Vascular protection — Counteracts major vessel occlusion syndromes by rapidly activating collateral blood vessel pathways. Shown effective in models of mesenteric vessel occlusion and in glaucoma models induced by episcleral vein cauterization.
- Organ protection — Cytoprotective effects observed across liver, kidney, heart, and brain tissue in various toxicity models, including protection against corticosteroid-induced muscle damage and lower-extremity ischemia-reperfusion-induced distant organ injury.
Critical Context — Research Independence
Over 80% of the ~190 PubMed-indexed BPC-157 articles list P. Sikiric or S. Seiwerth (University of Zagreb) as first or senior author. Independent laboratories have contributed only a handful of in vitro or short-term rodent studies. The most significant independent contribution is the Src-Caveolin-1-eNOS pathway work from Chang Gung University in Taiwan, and the Xu et al. preclinical safety evaluation in mice, rats, rabbits, and dogs. Heavy reliance on a single research group restricts generalizability and increases the risk of confirmation bias. The 2025 McGuire narrative review and the Józwiak 2025 literature-and-patent review both flag this as a meaningful limitation.
Human Data
As of April 2026, three published human pilot studies exist, all from the same research group:
- Intravenous safety pilot (Lee & Burgess, 2025; PMID 40131143) — IV BPC-157 administered at 10 mg followed by 20 mg the next day in two healthy adults. No adverse effects on cardiac, hepatic, renal, thyroid, or glucose biomarkers. Plasma clearance within 24 hours. N=2 is descriptive, not inferential.
- Interstitial cystitis pilot (Lee, Walker & Ayadi, 2024) — Intravesical BPC-157 in 12 women with moderate-to-severe interstitial cystitis who had failed first-line therapy (pentosan polysulfate). Reported 80–100% symptom resolution at 6 weeks. No control group, no blinding, small sample, single clinic.
- Chronic knee pain retrospective (Lee & Padgett, 2021) — 16 patients receiving intraarticular BPC-157 (alone or with thymosin beta-4) for various knee pain etiologies. 14 of 16 reported subjective improvement at 6–12 months recall. Uncontrolled, retrospective, subjective endpoint with heavy recall bias risk.
A Phase II trial investigating oral BPC-157 (PL 14736) for ulcerative colitis is registered on ClinicalTrials.gov (NCT05765058). An earlier Phase I safety/pharmacokinetics trial (NCT02637284) was registered but results were not submitted. No large-scale randomized controlled trials have been completed for any indication.
Outside of these three pilots, the vast majority of reports about human use are anecdotal: practitioner case reports, podcast interviews, and community forums. These are not the same as controlled evidence, and users should understand the difference when interpreting what they read online.
Dosing from the Literature
The following dosing information is derived from animal studies, allometric scaling, and practitioner reports. This is not medical advice.
| Route | Dose Range | Frequency | Notes |
|---|
| Subcutaneous | 250–500 mcg | 1–2x daily | Most commonly reported in practitioner protocols. Injected near the area of injury for localized effects. Rotate injection sites. |
| Oral | 250–500 mcg | 1–2x daily | Gastric stability makes oral viable. Primarily studied for GI applications. Take on an empty stomach ~30 minutes before meals. |
| Intramuscular | 250–500 mcg | 1–2x daily | Used in some practitioner protocols for deeper tissue injuries near major muscle groups. |
| Animal reference | 10 mcg/kg | Daily | Standard dose in most rat studies. Both 100 mcg/kg/day repeated IM and single 500 mcg/kg IM are well-tolerated by rats. No lethal dose (LD1) has been identified in toxicology studies. |
| Cycle length | 4–8 weeks | — | Followed by 2–4 weeks off. Some practitioners recommend shorter cycles (4 weeks) for acute injuries, longer for chronic conditions. |
Dosing Disclaimer
Optimal human dosing has not been established by controlled clinical trials. These doses are compiled from published preclinical research and practitioner reports for educational reference only. Individual response varies. Always work with a licensed healthcare provider.
Reconstitution & Storage
BPC-157 is typically supplied as a lyophilized (freeze-dried) powder in 5 mg or 10 mg vials.
| Vial Size | BAC Water | Concentration | 250 mcg Dose | 500 mcg Dose |
|---|
| 5 mg | 2 mL | 2,500 mcg/mL | 10 units (0.10 mL) | 20 units (0.20 mL) |
| 10 mg | 2 mL | 5,000 mcg/mL | 5 units (0.05 mL) | 10 units (0.10 mL) |
- Reconstitution — Inject bacteriostatic water slowly down the inside wall of the vial at a 45° angle. Swirl gently until dissolved — never shake. Solution should be clear and colorless.
- Storage — Lyophilized (unreconstituted) powder is stable at room temperature for 2+ years. After reconstitution, refrigerate at 2–8°C and use within 28 days. Do not freeze reconstituted solution.
- Inspection — Discard if solution shows cloudiness, visible particles, color change, or unusual odor.
→ Use the Kalios Dosing Calculator for exact syringe units
Side Effects & Risks
Important
BPC-157's safety profile in animals is remarkably clean. Human data is too small to draw firm conclusions. Share this with your clinician before acting.
BPC-157 has a generally favorable safety profile in the available preclinical research, but human data remains extremely limited:
- Reported side effects — GI discomfort (nausea, bloating), dizziness, headache, and injection site reactions. Most reports are anecdotal from community use rather than clinical trial data. The 2025 IV safety pilot (n=2) showed no adverse effects at doses up to 20 mg; the 2024 interstitial cystitis pilot (n=12) reported zero adverse events.
- Growth factor / tumor concerns — Because BPC-157 upregulates VEGFR2 and promotes angiogenesis, there is a theoretical concern about promoting growth in existing tumors or precancerous tissue. The Zagreb group claims anti-tumor properties based primarily on a single 2004 melanoma cell-line experiment, which has not been independently replicated, and no in vivo tumor-bearing host studies exist. Independent reviewers (Józwiak et al., 2025; McGuire et al., 2025) explicitly flag pro-angiogenic signaling as a plausible tumor-promoting hazard that has not been adequately studied. Cancer screening before starting BPC-157 is recommended by some practitioners.
- WADA banned substance — Banned by the World Anti-Doping Agency in 2022 under category S0 (non-approved substances). USADA has issued explicit advisories against use. Detection methods (UHPLC-HRMS) are now established. Athletes subject to anti-doping testing should not use BPC-157 under any circumstance.
- Purity and contamination — Gray market sourcing introduces significant variability. Independent testing has shown batch-to-batch inconsistency across vendors. An FDA analysis cited by multiple advocacy groups found that over 40% of peptide products sold through research-chemical channels contained inaccurate dosing, contamination, or degraded active compound. Purchase only lyophilized powder from vendors providing third-party Certificates of Analysis (COAs) showing purity above 98%.
- Drug interactions — Largely unstudied in humans. The NO system modulation suggests potential interactions with medications affecting vascular function (antihypertensives, nitrates, PDE5 inhibitors). Rodent studies show corticosteroids blunt BPC-157's tendon-healing effect, so concurrent corticosteroid injections may undermine the intended response.
- No identified lethal dose — Preclinical toxicology in mice, rats, rabbits, and dogs (Xu et al., 2020) identified no LD1 and no serious toxicity at doses many orders of magnitude above human practitioner ranges. This supports a wide therapeutic margin in animals but does not by itself establish human safety.
Bloodwork & Monitoring
No established clinical monitoring guidelines exist for BPC-157. Practitioners and informed users commonly track:
- Baseline CMP (comprehensive metabolic panel) — Liver and kidney function markers before starting any peptide protocol; repeat at 6–8 weeks.
- CBC (complete blood count) — Monitor for any hematological changes.
- Inflammatory markers — CRP and ESR can help track whether tissue repair is progressing.
- Vitamin D (25-OH) — Baseline and seasonal follow-up; common to be suboptimal in users with tendinopathy and slow-healing injuries.
- If GI application — Fecal calprotectin levels for objective tracking of intestinal inflammation; stool pattern diary for subjective tracking.
- Before/after imaging — For musculoskeletal applications, MRI or ultrasound (for tendon) gives objective evidence of tissue change rather than relying on subjective pain reports.
- Cancer screening — Given the theoretical pro-angiogenic concern, age-appropriate cancer screening before initiating long-duration protocols is reasonable. This is a risk-management, not a research-backed, recommendation.
Commonly Stacked With
The most common peptide stack for tissue repair. BPC-157 works primarily through local angiogenesis and growth factor upregulation; TB-500 acts systemically through actin polymerization and cell migration. Complementary mechanisms targeting different repair pathways. Commercially marketed as the "Wolverine Stack."
The 7-amino-acid actin-binding domain of Tβ4. A leaner, lower-cost alternative to full-length TB-500 for users who want the core cell-migration mechanism without the rest of the Tβ4 molecule. Sometimes paired with BPC-157 as a minimalist Wolverine Stack.
Added for skin rejuvenation and collagen synthesis. GHK-Cu modulates thousands of genes toward youthful expression via copper-dependent pathways — a different mechanism than BPC-157's growth factor / NO approach. Frequently combined as the GLOW Stack (GHK-Cu + BPC-157 + TB-500).
Anti-inflammatory tripeptide added for immune modulation. KPV suppresses NF-κB and reduces pro-inflammatory cytokines — targeting inflammation control while BPC-157 handles repair signaling. Combined as the KLOW Stack.
Growth hormone secretagogue stack. Some practitioners add BPC-157 to GH protocols during active injury recovery. The logic: elevated baseline GH supports the broader repair environment that BPC-157's local pathway-activation taps into.
→ Check compound compatibility in the Stack Builder
Regulatory Status
Current Status — April 2026
BPC-157 is currently classified as an FDA Category 2 bulk drug substance, meaning it is NOT eligible for use by compounding pharmacies under sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act.
On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. publicly announced an intention to reclassify approximately 14 of the 19 Category 2 peptides — BPC-157 among them — back to Category 1, which would make them available through licensed compounding pharmacies with a prescription. As of April 2026, the FDA has not published a formal update to the Category 1 list reflecting that announcement, and the Pharmacy Compounding Advisory Committee (PCAC) has not completed review. Practically, BPC-157 still cannot be legally compounded by 503A pharmacies as of this publication date.
BPC-157 is not approved by the FDA for any therapeutic indication. It is classified as a research chemical. It was banned by WADA in 2022 under S0 (non-approved substances). The proposed INN "Bepecin" was submitted by researchers, signaling intent for eventual pharmaceutical development. A Phase II ulcerative colitis trial (NCT05765058) and an earlier Phase I safety/PK registration (NCT02637284) have been recorded on ClinicalTrials.gov.
Cost & Access
BPC-157 is not approved for human use. It is available through research suppliers for laboratory research purposes only.
U.S. compounding pharmacies cannot legally compound BPC-157 under current FDA bulk-substance rules (Category 2 designation). Online research-chemical channels list BPC-157 at variable prices and quality, with purity varying substantially between vendors. Independent third-party Certificate of Analysis (HPLC purity + mass spec) is the practical floor for due diligence.
BPC-157 is among the peptides under HHS Secretary Robert F. Kennedy Jr.'s February 27, 2026 reclassification announcement. If reclassified back to Category 1 (subject to Pharmacy Compounding Advisory Committee review and FDA implementation), 503A compounded BPC-157 would likely be dispensed through licensed compounding pharmacies with a clinician's prescription. As of April 2026, this reclassification remains pending and BPC-157 cannot be legally compounded by 503A or 503B pharmacies in the United States.
Pricing and availability vary by provider, location, and prescription status. Kalios does not sell compounds.
Related Compounds
People researching BPC-157 often also look at these:
Three-way head-to-head of the top tissue-repair peptides. Mechanism, evidence, dosing, and why the three are stacked together in Wolverine and GLOW.
BPC-157 + TB-500 — the flagship tissue-repair protocol for tendon, ligament, and soft-tissue recovery.
GHK-Cu + BPC-157 + TB-500 — skin, hair, and collagen-focused repair protocol.
KPV + GHK-Cu + BPC-157 + TB-500 — anti-inflammatory and tissue-repair protocol emphasizing gut and immune modulation.
Short fragment of BPC-157 investigated for retaining the core cytoprotective activity at a lower molecular weight.
Erythropoietin-derived cytoprotective peptide targeting the innate repair receptor complex without hematopoietic effects.
Key References
- Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. PMID: 40756949. (544 articles screened, 36 studies included — the single most comprehensive systematic review to date.)
- McGuire FP, Martinez R, Lenz A, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025;18(12):611-619. PMID: 40789979.
- Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2):185. PMID: 40005999.
- Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025. PMID: 40131143.
- Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. 2024;30(10):12-17.
- Lee E, Padgett B. Intra-articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8-13.
- Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, Sever M, Klicek R, Radic B, Drmic D, Ilic S, Kolenc D, Vrcic H, Sebecic B. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-1632. PMID: 21548867.
- Seiwerth S, Rucman R, Turkovic B, et al. BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing. Curr Pharm Des. 2018;24(18):1972-1989. PMID: 29998800.
- Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. PMID: 27847966.
- Hsieh MJ, Lee CH, Chueh HY, Chang GJ, Huang HY, Lin Y, Pang JS. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Sci Rep. 2020;10(1):17078. PMID: 33051481. (Independent Taiwan data — the most important non-Zagreb mechanistic paper.)
- Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-19077. PMID: 25415472.
- Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. PMID: 14554208.
- Krivic A, Majerovic M, Jelic I, Seiwerth S, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res. 2006;24(5):982-989. PMID: 16583442.
- Sikiric P, Seiwerth S, Rucman R, et al. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Curr Neuropharmacol. 2016;14(8):857-865. PMID: 27138887.
- Vukojevic J, Milavic M, Perovic D, et al. Pentadecapeptide BPC 157 and the central nervous system. Neural Regen Res. 2022;17(3):482-487. PMID: 34380875.
- Xu C, Sun L, Ren F, Huang P, Tian Z, Cui J, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regul Toxicol Pharmacol. 2020;114:104665. (Independent safety study in mice, rats, rabbits, and dogs — no LD1 identified.)
- DeFoor MT, Dekker TJ. Injectable Therapeutic Peptides — An Adjunct to Regenerative Medicine and Sports Performance? Arthroscopy. 2025;41(2):150-163.
- USADA. BPC-157: Experimental Peptide Creates Risk for Athletes. U.S. Anti-Doping Agency. usada.org.
- ClinicalTrials.gov. Study of PL 14736 in Subjects With Ulcerative Colitis. NCT05765058.
- FDA. Bulk Drug Substances That Raise Significant Safety Risks (Category 2) Under Section 503A / 503B. FDA.gov. Updated 2025.
Last updated: April 2026 | Profile authored by Kalios Peptides research team